This initiative is intended to encourage the necessary later stages of development and validation of biomarkers with putative value for use in clinical trials, including multi-sites testing and validation for regulatory ‘context of use’ (e.g., diagnostic, enrichment, stratification).
via NIMH | Recent Updates http://ift.tt/1ng2Kaj